Gene expression analysis of peripheral T cell lymphoma, unspecified, reveals distinct profiles and new potential therapeutic targets

Journal of Clinical Investigation

Volumn 117, Issue 3, 2007, Pages 823-834

  Piccaluga, Pier Paolo ^a,b   Agostinelli, Claudio ^a   Califano, Andrea ^b   Rossi, Maura ^a   Basso, Katia ^b   Zupo, Simonetta ^c   Went, Philip ^a,d   Klein, Ulf ^b   Zinzani, Pier Luigi ^a   Baccarani, Michele ^b   Favera, Riccardo Dalla ^b   Pileri, Stefano A ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b Och Spine at New York Presbyterian Hospitals   (United States)

^c UNIVERSITY OF GENOA   (Italy)

^d UNIVERSITY OF BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

DAUNORUBICIN; HISTONE DEACETYLASE INHIBITOR; HLA DR ANTIGEN; IMATINIB; ITF 2357; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CARCINOGENESIS; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL ADHESION; CELL PROLIFERATION; DISEASE MARKER; DRUG MECHANISM; DRUG SENSITIVITY; GENE CONTROL; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; GENE LOCATION; GENE TARGETING; GENETIC ANALYSIS; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MORPHOLOGY; PERIPHERAL T CELL LYMPHOMA; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; T LYMPHOCYTE SUBPOPULATION; TREATMENT RESPONSE;

ADULT; AGED; APOPTOSIS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL ADHESION; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; HLA-DR ANTIGENS; HUMANS; LYMPHOCYTE ACTIVATION; LYMPHOMA, T-CELL, PERIPHERAL; MALE; MIDDLE AGED; NEOPLASM STAGING; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS;

EID: 33847402218     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI26833     Document Type: Article

References (81)

1. Jaffe, E.S., and Ralfkiaer, E. 2001. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. IARC Press. Lyon, France. 191-194.
2. Kadin, M.E., Berard, C.W., Nanba, K., and Wakasa, H. 1983. Lymphoproliferative diseases in Japan and Western countries: Proceedings of the United States-Japan Seminar, September 6 and 7, 1982, in Seattle, Washington. Hum. Pathol. 14:745-772.
3. Harris, N.L., et al. 1994. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood. 84:1361-1392.
4. Lopez-Guillermo, A., et al. 1998. Peripheral T-cell lymphomas: initial features, natural history, and prognostic factors in a series of 174 patients diag nosed according to the R.E.A.L. Classification. Ann. Oncol. 9:849-855.
5. Rizvi, M.A., Evens, A.M., Tallman, M.S., Nelson, B.P., and Rosen, S.T. 2006. T-cell non-Hodgkin lymphoma. Blood. 107:1255-1264.
6. Gisselbrecht, C., et al. 1998. Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas. Groupe d'Etudes des Lymphomes de l'Adulte (GELA). Blood. 92:76-82.
7. The Non-Hodgkin's Lymphoma Classification Project. 1997. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. Blood. 89:3909-3918.
8. Ascani, S., et al. 1997. Peripheral T-cell lymphomas. Clinico-pathologic study of 168 cases diagnosed according to the R.E.A.L. Classification. Ann. Oncol. 8:583-592.
9. Suchi, T., et al. 1987. Histopathology and immunohistochemistry of peripheral T cell lymphomas: a proposal for their classification. J. Clin. Pathol. 40:995-1015.
10. Patsouris, E., Engelhard, M., Zwingers, T., and Lennert, K. 1993. Lymphoepithelioid cell lymphoma (Lennert's lymphoma): clinical features derived from analysis of 108 cases. Br. J. Haematol. 84:346-348.
11. Hastrup, N., Ralfkiaer, E., and Pallesen, G. 1989. Aberrant phenotypes in peripheral T cell lymphomas. J. Clin. Pathol. 42:398-402.
12. Went, P., et al. 2006. Marker expression in peripheral T-cell lymphoma: a proposed clinical-pathologic prognostic score. J. Clin. Oncol. 24:2472-2479.
13. Greiner, T.C., Raffeld, M., Lutz, C., Dick, F., and Jaffe, E.S. 1995. Analysis of T cell receptor-gamma gene rearrangements by denaturing gradient gel electrophoresis of GC-clamped polymerase chain reaction products. Correlation with tumor-specific sequences. Am. J. Pathol. 146:46-55.
14. Lepretre, S., et al. 2000. Chromosome abnormalities in peripheral T-cell lymphoma. Cancer Genet. Cytogenet. 117:71-79.
15. Zettl, A., et al. 2004. Genomic profiling of peripheral T-cell lymphoma, unspecified, and anaplastic large T-cell lymphoma delineates novel recurrent chromosomal alterations. Am. J. Pathol. 164:1837-1848.
16. Gallamini, A., et al. 2004. Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Blood. 103:2474-2479.
17. Ferrando, A.A., et al. 2002. Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia. Cancer Cell. 1:75-87.
18. Tracey, L., et al. 2003. Mycosis fungoides shows concurrent deregulation of multiple genes involved in the TNF signaling pathway: an expression profile study. Blood. 102:1042-1050.
19. Martinez-Delgado, B., et al. 2004. Expression profiling of T-cell lymphomas differentiates peripheral and lymphoblastic lymphomas and defines survival related genes. Clin. Cancer Res. 10:4971-4982.
20. Mahadevan, D., et al. 2005. Transcript profiling in peripheral T-cell lymphoma, not otherwise specified, and diffuse large B-cell lymphoma identifies distinct tumor profile signatures. Mol. Cancer Ther. 4:1867-1879.
21. Ballester, B., et al. 2006. Gene expression profiling identifies molecular subgroups among nodal peripheral T-cell lymphomas. Oncogene. 25:1560-1570.
22. Hartigan, J.A. 1975. Clustering algorithms. John Wiley & Sons Inc. New York, New York, USA. 351 pp.
23. Eisen, M.B., Spellman, P.T., Brown, P.O., and Botstein, D. 1998. Cluster analysis and display of genome-wide expression patterns. Proc. Natl. Acad. Sci. U. S. A. 95:14863-14868.
24. + T cell differentiation. Int. Immunol. 16:1109-1124.
25. Chtanova, T., et al. 2004. T follicular helper cells express a distinctive transcriptional profile, reflecting their role as non-Th1/Th2 effector cells that provide help for B cells. J. Immunol. 173:68-78.
26. Chtanova, T., et al. 2005. Identification of T cell-restricted genes, and signatures for different T cell responses, using a comprehensive collection of microarray datasets. J. Immunol. 175:7837-7847.
27. Hosack, D.A., Dennis, G., Jr., Sherman, B.T., Lane, H.C., and Lempicki, R.A. 2003. Identifying biological themes within lists of genes with EASE. Genome Biol. 4:R70.
28. Tapper, J., et al. 2001. Changes in gene expression during progression of ovarian carcinoma. Cancer Genet. Cytogenet. 128:1-6.
29. Sado, Y., et al. 1998. Organization and expression of basement membrane collagen IV genes and their roles in human disorders. J. Biochem. (Tokyo). 123:767-776.
30. van den Boom, J., et al. 2003. Characterization of gene expression profiles associated with glioma progression using oligonucleotide-based microarray analysis and real-time reverse transcription-polymerase chain reaction. Am. J. Pathol. 163:1033-1043.
31. Schober, J.M., Lau, L.F., Ugarova, T.P., and Lam, S.C. 2003. Identification of a novel integrin alphaMbeta2 binding site in CCN1 (CYR61), a matricellular protein expressed in healing wounds and atherosclerotic lesions. J. Biol. Chem. 278:25808-25815.
32. Leu, S.J., et al. 2003. Identification of a novel integrin alpha 6 beta 1 binding site in the angiogenic inducer CCN1 (CYR61). J. Biol. Chem. 278:33801-33808.
33. Han, J.S., Macarak, E., Rosenbloom, J., Chung, K.C., and Chaqour, B. 2003. Regulation of Cyr61/CCN1 gene expression through RhoA GTPase and p38MAPK signaling pathways. Eur. J. Biochem. 270:3408-3421.
34. Tsai, M.S., Bogart, D.F., Castaneda, J.M., Li, P., and Lupu, R. 2002. Cyr61 promotes breast tumorigenesis and cancer progression. Oncogene. 21:8178-8185.
35. Tsai, M.S., Hornby, A.E., Lakins, J., and Lupu, R. 2000. Expression and function of CYR61, an angiogenic factor, in breast cancer cell lines and tumor biopsies. Cancer Res. 60:5603-5607.
36. Lin, M.T., et al. 2004. Cyr61 expression confers resistance to apoptosis in breast cancer MCF-7 cells by a mechanism of NF-kappaB-dependent XIAP up-regulation. J. Biol. Chem. 279:24015-24023.
37. Kassem, H., Sangar, V., Cowan, R., Clarke, N., and Margison, G.P. 2002. A potential role of heat shock proteins and nicotinamide N-methyl transferase in predicting response to radiation in bladder cancer. Int. J. Cancer. 101:454-460.
38. Xu, J., Capezzone, M., Xu, X., and Hershman, J.M. 2005. Activation of nicotinamide N-methyltransferase gene promoter by hepatocyte nuclear factor-1beta in human papillary thyroid cancer cells. Mol. Endocrinol. 19:527-539.
39. Heldin, C.H., and Westermark, B. 1999. Mechanism of action and in vivo role of platelet-derived growth factor. Physiol. Rev. 79:1283-1316.
40. Pardanani, A., and Tefferi, A. 2004. Imatinib targets other than bcr/abl and their clinical relevance in myeloid disorders. Blood. 104:1931-1939.
41. Jin, S., et al. 2002. GADD45-induced cell cycle G2-M arrest associates with altered subcellular distribution of cyclin B1 and is independent of p38 kinase activity. Oncogene. 21:8696-8704.
42. Papa, S., et al. 2004. Gadd45 beta mediates the NF-kappa B suppression of JNK signalling by targeting MKK7/JNKK2. Nat. Cell Biol. 6:146-153.
43. Chen, F., et al. 2001. Opposite effect of NF-kappa B and c-Jun N-terminal kinase on p53-independent GADD45 induction by arsenite. J. Biol. Chem. 276:11414-11419.
44. Hirose, T., et al. 2003. p53-independent induction of Gadd45 by histone deacetylase inhibitor: coordinate regulation by transcription factors Oct-1 and NF-Y. Oncogene. 22:7762-7773.
45. Piekarz, R.L., et al. 2001. Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report. Blood. 98:2865-2868.
46. Tamura, I., Rosenbloom, J., Macarak, E., and Chaqour, B. 2001. Regulation of Cyr61 gene expression by mechanical stretch through multiple signaling pathways. Am. J. Physiol. Cell Physiol. 281:C1524-C1532.
47. Jones, D., et al. 2000. Recurrences in nodal T-cell lymphoma. Changes in histologic appearance and immunophenotype over the course of disease. Am. J. Clin. Pathol. 114:438-447.
48. Chadburn, A., Inghirami, G., and Knowles, D.M. 1992. T-cell activation-associated antigen expression by neoplastic T-cells. Hematol. Pathol. 6:131-141.
49. Jones, D., Fletcher, C.D., Pulford, K., Shahsafaei, A., and Dorfman, D.M. 1999. The T-cell activation markers CD30 and OX40/CD134 are expressed in nonoverlapping subsets of peripheral T-cell lymphoma. Blood. 93:3487-3493.
50. Gu, J., Fujibayashi, A., Yamada, K.M., and Sekiguchi, K. 2002. Laminin-10/11 and fibronectin differentially prevent apoptosis induced by serum removal via phosphatidylinositol 3-kinase/Akt- and MEK1/ERK-dependent pathways. J. Biol. Chem. 277:19922-19928.
51. Tan, K.O., et al. 2001. MAP-1, a novel proapoptotic protein containing a BH3-like motif that associates with Bax through its Bcl-2 homology domains. J. Biol. Chem. 276:2802-2807.
52. Nagashima, M., et al. 2003. A novel PHD-finger motif protein, p47ING3, modulates p53-mediated transcription, cell cycle control, and apoptosis. Oncogene. 22:343-350.
53. Gunduz, M., et al. 2002. Allelic loss and reduced expression of the ING3, a candidate tumor suppressor gene at 7q31, in human head and neck cancers. Oncogene. 21:4462-4470.
54. Peng, B., et al. 2004. Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients. J. Clin. Oncol. 22:935-942.
55. Basciani, S., et al. 2005. Imatinib mesylate inhibits Leydig cell tumor growth: evidence for in vitro and in vivo activity. Cancer Res. 65:1897-1903.
56. Decaudin, D., et al. 2005. In vivo efficacy of STI571 in xenografted human small cell lung cancer alone or combined with chemotherapy. Int. J. Cancer. 113:849-856.
57. Sanchez-Gonzalez, B., et al. 2006. Antileukemia activity of the combination of an anthracycline with a histone deacetylase inhibitor. Blood. 108:1174-1182.
58. Martinez-Delgado, B., et al. 2005. Differential expression of NF-kappaB pathway genes among peripheral T-cell lymphomas. Leukemia. 19:2254-2263.
59. Gotlib, J., et al. 2004. The FIP1L1-PDGFRalpha fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management. Blood. 103:2879-2891.
60. George, D. 2003. Targeting PDGF receptors in cancer: rationales and proof of concept clinical trials. Adv. Exp. Med. Biol. 532:141-151.
61. Heinrich, M.C., et al. 2003. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J. Clin. Oncol. 21:4342-4349.
62. Stone, R.M., Gilliland, D.G., and Klion, A.D. 2004. Platelet-derived growth factor receptor inhibition to treat idiopathic hypereosinophilic syndrome. Semin. Oncol. 31:12-17.
63. Pardanani, A., et al. 2003. Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorders. Blood. 101:3391-3397.
64. Klein, U., et al. 2001. Gene expression profiling of B cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B cells. J. Exp. Med. 194:1625-1638.
65. Liu, C.G., et al. 2004. An oligonucleotide microchip for genome-wide microRNA profiling in human and mouse tissues. Proc. Natl. Acad. Sci. U. S. A. 101:9740-9744.
66. Basso, K., et al. 2004. Gene expression profiling of hairy cell leukemia reveals a phenotype related to memory B cells with altered expression of chemokine and adhesion receptors. J. Exp. Med. 199:59-68.
67. Califano, A. 2000. SPLASH: structural pattern localization analysis by sequential histograms. Bioinformatics. 16:341-357.
68. Califano, A., Stolovitzky, G., and Tu, Y. 2000. Analysis of gene expression microarrays for phenotype classification. Proc. Int. Conf. Intell. Syst. Mol. Biol. 8:75-85.
69. Jenssen, T.K., Laegreid, A., Komorowski, J., and Hovig, E. 2001. A literature network of human genes for high-throughput analysis of gene expression. Nat. Genet. 28:21-28.
70. Pileri, S.A., et al. 1997. Antigen retrieval techniques in immunohistochemistry: comparison of different methods. J. Pathol. 183:116-123.
71. Xie, D., et al. 2004. Levels of expression of CYR61 and CTGF are prognostic for tumor progression and survival of individuals with gliomas. Clin. Cancer Res. 10:2072-2081.
72. Brown, R.E., and Nazmi, R.K. 2002. The Reed-Steinberg cell: molecular characterization by proteomic analysis with therapeutic implications. Ann. Clin. Lab. Sci. 32:339-351.
73. Savarese, T.M., et al. 2002. Coexpression of oncostatin M and its receptors and evidence for STAT3 activation in human ovarian carcinomas. Cytokine. 17:324-334.
74. Ye, H., et al. 2000. BCL10 expression in normal and neoplastic lymphoid tissue. Nuclear localization in MALT lymphoma. Am. J. Pathol. 157:1147-1154.
75. Degeorges, A., Wang, F., Frierson, H.F., Jr., Seth, A., and Sikes, R.A. 2000. Distribution of IGFBP-rP1 in normal human tissues. J. Histochem. Cytochem. 48:747-754.
76. Zheng, P.P., et al. 2004. Differential expression of splicing variants of the human caldesmon gene (CALD1) in glioma neovascularization versus normal brain microvasculature. Am. J. Pathol. 164:2217-2228.
77. Fredersdorf, S., et al. 1997. High level expression of p27(kip1) and cyclin D1 in some human breast cancer cells: inverse correlation between the expression of p27(kip1) and degree of malignancy in human breast and colorectal cancers. Proc. Natl. Acad. Sci. U. S. A. 94:6380-6385.
78. Sabattini, E., et al. 1998. The EnVision++ system: a new immunohistochemical method for diagnostics and research. Critical comparison with the APAAP, ChemMate, CSA, LABC, and SABC techniques. J. Clin. Pathol. 51:506-511.
79. Cools, J., Stover, E.H., Wlodarska, I., Marynen, P., and Gilliland, D.G. 2004. The FIP1L1-PDGFRalpha kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia. Curr. Opin. Hematol. 11:51-57.
80. Gilliland, G., Cools, J., Stover, E.H., Wlodarska, I., and Marynen, P. 2004. FIP1L1-PDGFRalpha in hypereosinophilic syndrome and mastocytosis. Hematol. J. 5(Suppl. 3):S133-S137.
81. Lev, D.C., et al. 2005. Inhibition of platelet-derived growth factor receptor signaling restricts the growth of human breast cancer in the bone of nude mice. Clin. Cancer Res. 11:306-314.